Navigation Links
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
Date:11/13/2012

CASTLE ROCK, Colo., Nov. 13, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that it will present at the 9th Annual Lazard Capital Markets Healthcare Conference, held November 13-14, 2012, at the Pierre Hotel in New York City.  

Steve Lundy, President and CEO of AspenBio, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.Event:2012 Lazard Capital Markets Healthcare ConferenceDate: Wednesday, November 14, 2012 Time: 2:30 pm (Eastern Time) Location:Regency B room; Pierre Hotel, New York, NYAbout AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com 
jrando@tiberend.com

 


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AspenBio to Present at 2012 Aegis Healthcare Conference
2. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Regulus to Present at the Lazard Capital Markets Healthcare Conference
7. Heptares to Present at BIO-Europe 2012
8. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
9. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Organovo To Present At Lazard Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017 This report analyzes the worldwide markets for ... Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Read the full ... are provided for the period 2015 through 2022. Also, a ...
(Date:2/20/2017)... FL (PRWEB) , ... February ... ... the leading US Joint Commission Accredited venture-backed teleradiology and telemedicine company announces ... Siemens Healthineers. USARAD services are planned to be offered via a global ...
(Date:2/20/2017)... -- Former NFL players who had repeated head injuries may not ... to a preliminary study released today that will be presented ... Boston , April 22 to 28, 2017. ... muscles and nerves work together, like walking, kicking and writing. ... Repeated ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include ... weighing equipment with the goal of expanding the reach of its quality and ... Starter water analysis meters were introduced into the market in 2014. , The ...
Breaking Biology Technology:
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... Jan. 19, 2017 Sensory Inc ... and security for consumer electronics, and i ... systems and cybersecurity solutions, today announced a global ... financial institutions worldwide to bolster security of data ... secure user authentication platforms they offer, innerCore now ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
Breaking Biology News(10 mins):